Drug search by name

PCE Dispertab and Rifadin IV

Determining the interaction of PCE Dispertab and Rifadin IV and the possibility of their joint administration.

Check result:

PCE Dispertab <> Rifadin IV

Relevance: 03.12.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Ask your doctor before using erythromycin together with rifAMPin. This can alter your blood levels or add to the side effects of either medication. Call the doctor if you have side effects such as nausea, vomiting and diarrhea. This combination can also affect the eye and cause inflammation of part or all of the uvea, the middle part of the eye. You may need a dose adjustment or special tests to safely take both medications together. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

GENERALLY AVOID: The coadministration of clarithromycin and rifabutin at normally recommended dosages has been reported to have resulted in significantly altered pharmacokinetics for both drugs. In a study of 34 clinically stable subjects with advanced HIV infection (CD4 less than 200 cells/mm3), the addition of rifabutin in patients stabilized on clarithromycin therapy slowly decreased the clarithromycin area under the plasma concentration-time curve (AUC) and C(max) up to an average of 44% and 41%, respectively, at the end of 4 weeks of combination therapy. In patients stabilized on rifabutin therapy, the addition of clarithromycin significantly increased rifabutin AUC and C(max) after the first dose. After 4 weeks, average increases of 99% and 69%, respectively, were reported. This bidirectional interaction is consistent with rifabutin's cumulative inducing effect over time on the CYP450 enzymatic pathway as well as clarithromycin's immediate inhibiting effect on the pathway. In the study, the combination was tolerated by more than 90% of the patients. However, 66% of them experienced gastrointestinal problems including nausea, vomiting and diarrhea. An increased incidence of uveitis has also been reported with this combination. In addition, the combination of clarithromycin and rifampin 600 mg/day (with multiple other drugs) decreased clarithromycin serum levels by approximately 90%. Other macrolide antibiotics may interact in a similar manner with rifamycins.

MANAGEMENT: Some experts recommend that this combination be avoided since it may result in decreased efficacy of the macrolide and increased rifamycin toxicity (e.g, neutropenia, uveitis).

References

Wallace RJ, Brown BA, Griffith DE, Girard W, Tanaka K "Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium -M.intracellulare infection." J Infect Dis 171 (1995): 747-50
Apseloff G, Foulds G, LaBoy-Goral L, Willavize S, Vincent J "Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers." J Clin Pharmacol 38 (1998): 830-5
von Rosenstiel NA, Adam D "Macrolide antibacterials. Drug interactions of clinical significance." Drug Saf 13 (1995): 105-22
Griffith DE, Brown BA, Girard WM, Wallace RJ Jr "Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease." Clin Infect Dis 21 (1995): 594-8
Benson CA, Williams PL, Cohn DL, Becker S, Hojczyk P, Nevin T, Korvick JA, Heifets L, Child CC, Lederman MM, Reichman RC, "Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial." J Infec Dis 181 (2000): 1289-97
Jordan MK, Polis MA, Kelly G, Narang PK, Masur H, Piscitelli SC "Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics." Antimicrob Agents Chemother 44 (2000): 2170-72
Hafner R, Bethel J, Power M, et al. "Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers." Antimicrob Agents Chemother 42 (1998): 631-9
Benson CA, Williams PL, Currier JS, et al. "A Prospective, Randomized Trial Examining the Efficacy and Safety of Clarithromycin in Combination with Ethambutol, Rifabutin, or Both for the Treatment of Disseminated Mycobacterium avium Complex Disease in Persons with Acquired Immunodeficiency Syndrome" Clin Infect Dis 37 (2003): 1234-43

PCE Dispertab

Generic Name: erythromycin

Brand name: EES. Granules, EES-400 Filmtab, EryPed 200, EryPed 400, Ery-Tab, Erythrocin Lactobionate, Erythrocin Stearate Filmtab, PCE Dispertab, E. E. S, EryPed, Erythrocin, Erythromycin Filmtabs, Erythromycin Lactobionate - IV

Synonyms: PCE Dispertab (Oral), PCE, PCE (Oral)

What is PCE Dispertab?

Rifadin IV

Generic Name: rifampin

Brand name: Rifadin IV, Rifadin, Rimactane

Synonyms: n.a.

What is Rifadin IV?

+ Add a drug Remove all

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

The list of popular interactions